Can A Cancer Cure Overcome Evolutionary Pressure?

·32 min·2 clips

Dr. Weavey says cancer is a "swarm" and that curative therapy usually needs "multi-drug or multi-modality" treatment.

1. Nature and Science Podcast frames cancer as a problem shaped by biology, evolution, and treatment history. 2. Don Murphy hosts Dr. Robert Weavey, a chemotherapy oncologist in Raleigh, and Dr. Roger Anderson, a radiation oncologist and University of Wisconsin professor. 3. The episode asks whether a cancer cure is realistic or whether cancer will remain part of human evolution. 4. Dr. Weavey says he moved from science and a joint MD-PhD path into oncology during the HIV epidemic and Kaposi's sarcoma care. 5. Dr. Weavey defines oncology as the internal-medicine subspecialty dealing with leukemias, lymphomas, and solid tumors like lung and colon cancer. 6. Dr. Anderson describes a circuitous route from Durham, North Carolina, with early exposure to doctors, labs, and heart-surgery pioneers. 7. Dr. Anderson recalls childhood visits to Don Hackle's lab and to physician Will Seeley, who worked on electrophysiology and Wolff-Parkinson-White syndrome. 8. Dr. Anderson also says he was interested in biochemistry and became more drawn to people than to laboratory work. 9. The episode links cancer history to changing scientific categories, including the move from one kind of lung cancer to multiple recognized types. 10. Both doctors note that cancer was once thought to be infectious, which shaped how people reacted to patients. 11. Dr. Weavey explains cancer as genome instability, imperfect replication, failed proofreading, and environmental carcinogens under selective pressure. 12. He says that same instability drives evolution, which is why cancer is tied to the biology that makes humans what they are. 13. Dr. Weavey argues that public health measures, vaccines, screening, and early treatment could affect "three-quarters of all cancers." 14. He uses his own HPV-related cancer treatment as an example of early detection followed by chemotherapy and radiation. 15. Dr. Anderson says radiation use has shifted from early 20th-century practice to more sophisticated protocols guided by historical precedent and clinical trials. 16. Dr. Weavey adds that clinical trial data determine when treatment should be limited, especially when evidence shows shorter therapy can work as well as longer therapy. 17. Dr. Anderson says targeted therapy may reduce side effects, and pediatrics already aims to avoid radiation when possible because of long-term harm. 18. Dr. Weavey says cancer behaves like a heterogeneous swarm, so selective pressure can leave resistant cells behind after treatment. 19. The conversation has an explanatory, interview-style tone with long answers, frequent interruptions, and analogies to infectious disease, TB, and Betty Crocker. 20. Listeners interested in oncology, screening, and cancer evolution will likely stay; listeners wanting a fast, nontechnical discussion may skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Nature and Science Podcast